NCT01772420View on ClinicalTrials.gov

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions
Adult Myelodysplastic SyndromeAnemiaChronic Myelomonocytic Leukemia
Interventions
DRUG

Eltrombopag Olamine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Trial Locations (2)

10461

Albert Einstein College of Medicine, The Bronx

66160

University of Kansas Cancer Center, Kansas City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Albert Einstein College of Medicine

OTHER

NCT01772420 - Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia | Biotech Hunter | Biotech Hunter